• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Carbohydrate metabolism in relation to hormonal replacement therapy.

作者信息

Notelovitz M

出版信息

Acta Obstet Gynecol Scand Suppl. 1981;106:51-6. doi: 10.3109/00016348209155331.

DOI:10.3109/00016348209155331
PMID:7042837
Abstract

The effect of hormone replacement therapy on carbohydrate metabolism in menopausal women is briefly reviewed. Estrogen treatment has bi-phasic effect; abnormal glucose tolerance with a normal insulin level is commonly found within 3 months of treatment, followed by normalization of the glycemia when treatment is extended beyond one year. Normal tolerance usually occurs once treatment is stopped. Estrogens may therefore be regarded as being glucogenic (reversible blood glucose elevation) rather than diabetogenic (permanent hyperglycemia). With some exceptions, progestogens have little effect on glucose tolerance within the first 3-6 months of treatment; thereafter progressive hyperglycemia and hyperinsulinemia occur. Postulated mechanisms for the hormonal effect on carbohydrate metabolism are noted, including the possible synergistic effect of estrogens on progestogen glucogenic activity. The significance of chronic hyperglycemia and vascular disease is commented upon.

摘要

相似文献

1
Carbohydrate metabolism in relation to hormonal replacement therapy.
Acta Obstet Gynecol Scand Suppl. 1981;106:51-6. doi: 10.3109/00016348209155331.
2
Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.雌激素、孕激素及低剂量口服避孕药治疗期间的碳水化合物代谢
Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):732-4. doi: 10.1016/s0002-9378(16)32479-6.
3
[Estrogens, progestins and glucido-lipid metabolism].
Rev Prat. 1993 Dec 15;43(20):2625-9.
4
Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.口服避孕药、碳水化合物代谢异常与心血管疾病发生之间关系的临床研究
Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):334-43. doi: 10.1016/0002-9378(90)90578-u.
5
Contraception for the perimenopausal patient.围绝经期患者的避孕
Obstet Gynecol Clin North Am. 1987 Mar;14(1):207-27.
6
Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.1型和2型糖尿病女性使用激素与非激素避孕药的情况
Cochrane Database Syst Rev. 2006 Oct 18(4):CD003990. doi: 10.1002/14651858.CD003990.pub3.
7
Glycaemic control and hormone replacement therapy: implications of the Postmenopausal Estrogen/Progestogen Intervention (PEPI) study.血糖控制与激素替代疗法:绝经后雌激素/孕激素干预(PEPI)研究的启示
Drugs Aging. 2000 Dec;17(6):453-61. doi: 10.2165/00002512-200017060-00003.
8
Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.口服避孕药与冠心病:孕激素对葡萄糖耐量和血浆脂质危险因素的调节作用。
Am J Obstet Gynecol. 1988 Jun;158(6 Pt 2):1612-20. doi: 10.1016/0002-9378(88)90199-8.
9
[Oral contraceptives, carbohydrate metabolism and diabetes mellitus].
Sem Hop. 1983 Dec 8;59(45):3162-6.
10
Effects of estrogens and progestogens on lipid metabolism.雌激素和孕激素对脂质代谢的影响。
Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):773-5. doi: 10.1016/s0002-9378(16)32487-5.

引用本文的文献

1
Translating safety, efficacy and compliance into economic value for controlled release dosage forms.将控释剂型的安全性、有效性和依从性转化为经济价值。
Pharmacoeconomics. 1994 Jun;5(6):482-504. doi: 10.2165/00019053-199405060-00005.